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Helminths trigger multiple immunomodulatory pathways that can
protect from sepsis. Human resistin (hRetn) is an immune cell-derived
protein that is highly elevated in helminth infection and sepsis.
However, the function of hRetn in sepsis, or whether hRetn influences
helminth protection against sepsis, is unknown. Employing hRetn-
expressing transgenic mice (hRETNTg+) and recombinant hRetn,
we identify a therapeutic function for hRetn in lipopolysaccharide
(LPS)-induced septic shock. hRetn promoted helminth-induced immu-
nomodulation, with increased survival of Nippostrongylus brasilien-
sis (Nb)-infected hRETNTg+ mice after a fatal LPS dose compared
with naive mice or Nb-infected hRETNTg−mice. Employing immuno-
precipitation assays, hRETNTg+Tlr4−/−mice, and human immune cell
culture, we demonstrate that hRetn binds the LPS receptor Toll-like
receptor 4 (TLR4) through its N terminal and modulates STAT3 and
TBK1 signaling, triggering a switch from proinflammatory to anti-
inflammatory responses. Further, we generate hRetn N-terminal pep-
tides that are able to block LPS proinflammatory function. Together,
our studies identify a critical role for hRetn in blocking LPS function
with important clinical significance in helminth-induced immunomodu-
lation and sepsis.
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In the United States, 750,000 people are diagnosed with sepsiseach year, with a mortality rate of 30% (1). Sepsis pathogenesis
is exacerbated by the inflammatory response to the pathogen-
associated molecular pattern ligand lipopolysaccharide (LPS), a
main component of Gram-negative bacterial cell walls. LPS
binds to Toll-like receptor 4 (TLR4) and induces a NF-κB-
dependent inflammatory cascade resulting in excessive pro-
duction of tumor necrosis factor alpha (TNFα) and interleukin 6
(IL-6). These proinflammatory cytokines are initially beneficial
in bacterial killing, but eventually damage the host’s cells and tis-
sues. For instance, excessive production of TNFα causes endo-
thelial cell injury, leading to vascular permeability, low blood
pressure, and organ failure (2). Recent studies have targeted this
innate inflammatory pathway as a potential treatment for sepsis.
Tlr4−/− mice or mice treated with anti-TLR4 antibodies were re-
sistant to Escherichia coli-induced sepsis as a result of reduced
proinflammatory cytokines (3). Nonetheless, clinical trials with
anti-TLR4 antibodies or TLR4 antagonists have not been suc-
cessful (4), and treatment for sepsis is currently limited to antibi-
otics and supportive care. Epidemiological studies show that sepsis
can result from other infections, including Gram-positive bacteria,
viruses, or fungi, which also stimulate an excessive inflammatory
response (1). Given the lack of specific treatments for sepsis and
the high incidence of sepsis in multiple infections, it is critical to
identify regulatory pathways that mitigate sepsis pathogenesis.
Helminth infections trigger multiple immunomodulatory path-
ways that protect against inflammatory diseases including nflam-
matory bowel disease and sepsis (5, 6). Helminths can cause
debilitating symptoms including anemia, intestinal blockage, and
malnutrition, therefore, identifying the specific pathways that are
protective against inflammatory diseases is necessary to avoid
the pathogenic consequences of helminth infection. Recent
studies have shown that chronic infection with filarial nematode
Litomosoides sigmodontis protects mice from fatal sepsis through
TLR2-dependent activation of macrophages and inhibition of
proinflammatory cytokines (6). In addition, helminth antigens
such as Acanthocheilonema viteae ES-62 and Fasciola hepatica
fatty acid binding protein bind to TLR4 and reduce proin-
flammatory cytokine production (7, 8).
Human resistin (hRetn), a member of the resistin-like molecule
(RELM) family of secreted proteins, is expressed in many in-
flammatory diseases, such as diabetes (9), atherosclerosis (10), and
rheumatoid arthritis (11). A recent study identifying a causal link
between the immune system and chronic fatigue syndrome repor-
ted differential resistin expression. Intriguingly, they found that
resistin levels correlated with reduced disease severity in patients
with moderate to severe disease, but observed the opposite trend in
mild to moderate disease groups (12). Elevated hRetn expression is
also observed in infectious settings, including helminth, bacterial,
and viral infection (13, 14), and in sepsis (15). Several studies
have shown that LPS promotes high-level expression of hRetn in
vitro and in vivo (16, 17). Functionally, hRetn increased the pro-
duction of proinflammatory cytokines, promoted the formation of
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neutrophil extracellular traps, and exacerbated acute LPS-induced
lung injury (18). In clinical reports, increased circulating hRetn has
been correlated with the severity of sepsis, leading to the sugges-
tion of hRetn as a diagnostic marker of sepsis (15). However,
mechanistic studies investigating the function of hRetn in sepsis
have not been performed.
Here, we use transgenic mice that express hRetn (hRETNTg+)
to study the function of hRetn in a mouse model of sepsis. LPS
injection resulted in significantly increased circulating hRetn in
the hRETNTg+mice, which were critically protected against fatal
LPS-induced inflammation compared with littermate control
hRETNTg− mice. Further, therapeutic treatment with recombi-
nant hRetn protected C57BL/6 mice against LPS-induced mor-
tality. We tested whether hRetn contributed to helminth-induced
immunomodulation and observed that hRetn enhanced the
protective effects of Nippostrongylus brasiliensis (Nb) infection in
LPS-induced endotoxic shock. Mechanistically, hRetn inhibited
LPS-induced neutrophilia and promoted a shift from a proin-
flammatory signaling (e.g., TNFα, NF-κB) to an anti-inflammatory
pathway (e.g., IL-10, STAT3). hRetn has been proposed to bind
TLR4 (19); however, more recent studies have questioned this
interaction (20). Combining protein modeling, hRetn N-peptide
synthesis, and immunoprecipitation assays, we provide direct evi-
dence that hRetn binds TLR4 through the N-terminal helix and
competes for the binding of the coreceptor MD2. In functional
assays with human peripheral blood mononuclear cells (PBMC),
we show that hRetn binding to TLR4 prevents subsequent
LPS binding and inflammatory function through a STAT3- and
TBK1-dependent mechanism. To test the effect of hRetn on
TLR4 signaling in vivo, we generated hRETNTg+ mice on the
Tlr4−/− background and observed that the anti-inflammatory ef-
fects of hRetn were TLR4-dependent. Together, our studies
identify a previously unrecognized role for hRetn in blocking LPS
function and promoting anti-inflammatory pathways with impor-
tant clinical implications for helminth-induced immunomodulation
and sepsis.
Results
hRETNTg+ Mice Are Resistant to LPS-Induced Inflammation and
Mortality. Previous studies have shown that LPS induces ex-
pression of hRETN, which promotes proinflammatory cytokines,
and that septic patients exhibit a high level of circulating hRetn
(15). These data suggest hRetn is pathogenic in LPS-induced
inflammation and sepsis; however, functional studies testing
hRetn effects on sepsis pathogenesis have not been performed. To
investigate this in vivo, we used transgenic mice that express hRetn
(hRETNTg+) in a mouse model of LPS-induced septic shock (Fig.
1A). hRETNTg+ mice were previously generated by bacterial ar-
tificial chromosome-mediated integration of the hRETN gene and
regulatory region on a mouse resistin (mRetn−/−) background.
Characterization of these mice revealed that circulating hRetn
levels are comparable to humans and that hRetn is significantly up-
regulated in vivo after LPS injection (16, 17). In our studies, mice
were challenged intraperitoneally (i.p.) with a low dose of LPS to
induce hRetn expression in hRETNTg+ mice, followed by a second
fatal dose of LPS. Low-dose LPS led to significantly increased
circulating hRetn in the hRETNTg+ mice (Fig. 1B). Strikingly,
hRetn expression was protective against the fatal LPS dose, with
significantly improved survival of hRETNTg+ mice compared
with littermate control hRETNTg− mice (Fig. 1C, blue vs. black).
Although this two-dose LPS model may result in some endotoxin
tolerance, this tolerance was not sufficient to protect against fatal
endotoxic shock in the absence of hRetn. We investigated the
physiological and immune mechanism by which hRetn protected
against LPS-induced mortality. Compared with hRETNTg− mice,
hRETNTg+ mice were protected from LPS-induced hypothermia
(Fig. 1D). Flow cytometric analysis of the peritoneal exudate
cells (PEC) from naive mice revealed equivalent frequencies of
macrophages, neutrophils, and monocytes, but increased eosino-
phils in hRETNTg+ mice compared with hRETNTg− mice (Fig.
1E). After LPS treatment, the protective response in hRETNTg+
mice coincided with significantly reduced neutrophils and in-
creased eosinophils compared with hRETNTg− mice, suggesting
a shift from a proinflammatory response to a T helper type
2 immune response. We also observed a significant increase in
monocyte frequency, consistent with our previous finding that
hRetn promotes monocyte recruitment (13). To identify cytokines
that may contribute to hRetn-mediated protection against sepsis,
we analyzed by Luminex the serum of LPS-treated hRETNTg− or
hRETNTg+ mice for a panel of 33 cytokines (Table S1). LPS-
treated hRETNTg+ mice exhibited a decrease in circulating
proinflammatory and Th1 cytokines [e.g., TNFα, interferon gamma
(IFNγ), IL-6, IL-12, IL-1α, and granulocyte-macrophage colony-
stimulating factor (GM-CSF)] compared with hRETNTg− mice
(Fig. 1 F and G). Conversely, the anti-inflammatory cytokine
IL-10 was increased in hRETNTg+ mice.
Given that the hRETN transgene was randomly integrated into
the mouse genome, the protective effects observed in the trans-
genic mice could be a result of disruption of another gene. We
generated a second transgenic mouse line (Tg2) and confirmed
high circulating hRetn levels after LPS treatment (Fig. 1B).
Compared with hRETNTg− mice, Tg2 mice were also protected
against the fatal LPS dose, exhibiting 100% survival (Fig. 1C,
green). We also used single nucleotide polymorphism analysis,
available at Dartmouse, to locate the hRETN gene insertion sites
in the transgenic mice at a resolution of 0.5 Mbp. In both trans-
genic mouse lines, hRETN gene insertions were predicted in
noncoding regions or intron sites (Table S2). Because the hRETN
transgene insertion did not disrupt coding regions, and there is no
overlap between insert locations in the hRETNTg+ and Tg2 mice,
it is unlikely that the protection conferred by the hRETN trans-
gene in both mouse lines is an artifact of the transgene inser-
tion. Both hRETN transgenic mouse lines were generated on a
mRetn−/− background; therefore, we included C57BL/6 mice in the
LPS-induced septic shock model to account for potential effects of
endogenous mRetn. In contrast to hRETNTg+ mice, C57BL/6
mice succumbed to the fatal LPS dose and mortality was correlated
with increased circulating inflammatory cytokines (IL-6, TNFα,
and IFNγ) and decreased IL-10. Interestingly, C57BL/6 mice had
increased serum IL-6 and IFNγ over hRETNTg− mice, suggesting
endogenous mRetn may increase these cytokines. However, this
potential functional effect of mRetn did not affect survival out-
come, with no significant differences in survival rate between
hRETNTg− and C57BL/6 mice.
Together, these data identify an anti-inflammatory role for
hRetn in endotoxic shock. Because neutrophils contribute to
sepsis progression through the production of reactive oxygen
species and proinflammatory cytokines (21), the reduction of
neutrophils and proinflammatory cytokines in hRetn-expressing
mice likely contributes to the reduced mortality during endo-
toxic shock. The increase in IL-10 may be a result of the increase
in eosinophil numbers, as eosinophils have been shown to be a
significant source of IL-10 (22). Alternatively, monocytes, poten-
tially induced by the increased macrophage colony-stimulating
factor (M-CSF) in the hRETNTg+ mice, may have contributed
to the increase in IL-10. This report shows a protective function
for hRetn in reducing fatal LPS-induced mortality and challenges
the current paradigm that resistin is an inflammatory cytokine that
exacerbates sepsis pathogenesis.
Therapeutic Administration of hRetn Ameliorates LPS-Induced
Inflammation and Mortality. As a complementary approach to
hRETNTg+ mice, we investigated whether intraperitoneal (i.p.)
treatment with recombinant hRetn was protective against en-
dotoxic shock (Fig. 2A). Because we used recombinant hRetn in
C57BL/6 mice, a preliminary dose of LPS was not necessary to
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induce hRetn expression and limited confounding factors caused
by potential endotoxin tolerance. Compared with control
C57BL/6 mice, which succumbed to LPS-induced sepsis, mice
treated with recombinant hRetn were resistant to LPS-induced
mortality (Fig. 2B). hRetn-mediated effects were associated with
a modest protection from the LPS-induced temperature drop,
and significantly reduced LPS-induced vascular permeability
(Fig. 2 C and D). Associated with hRetn-mediated protection
from sepsis pathogenesis, we observed a significant reduction in
proinflammatory cytokines TNFα, IL-6, and IFNγ, but no change
in IL-10 expression (Fig. 2E). Similar to the hRETNTg+ mice,
hRetn-treated mice exhibited significantly reduced LPS-induced
neutrophils in the peritoneal cavity and increased monocytes
(Fig. 2F). The recombinant hRetn used was generated in bac-
teria, but had an undetectable endotoxin (≤0.016 U/μg) when
quantified by the limulus amebocyte lysate (LAL) assay. To-
gether, these results demonstrate that both transgenic expression
of hRETN and hRetn treatment are critically protective in a
mouse model of sepsis by limiting proinflammatory cytokine
expression. Treatment with hRetn did not entirely recapitulate
the phenotype in hRETNTg+ mice; notably, the differences in
eosinophils and IL-10 expression. These differences are possibly
a result of effects of timing of expression, or half-life or locali-
zation of the recombinant hRetn. Nonetheless, the protective
effect of exogenous hRetn treatment supports the therapeutic
potential of hRetn in altering the outcome of septic shock.
Helminth Infection-Induced hRetn Protects Against Sepsis. Helminth
infections are associated with an increase in circulating
LPS, presumably because of organ damage or an increase in in-
testinal barrier permeability (23). However, there are numerous
helminth-mediated immunoregulatory mechanisms in place to
limit excessive LPS inflammatory responses, including sepsis (6).
We previously showed that both filarial nematode- and soil-
transmitted helminth-infected individuals exhibited increased cir-
culating hRetn (13). In addition, Nb-infected hRETNTg+ mice
had significantly elevated hRetn in the infected tissue, which im-
paired optimal helminth expulsion. We hypothesized that instead of
Fig. 1. hRetn protects against endotoxic shock.
(A) Experimental design of LPS-induced sepsis model.
(B) hRetn serum levels in hRETNTg+ and Tg2+ mice
were measured by ELISA. (C) Survival rate was eval-
uated after high-dose LPS (12 mg/kg) injection. (D)
Rectal body temperature was measured at 0 and 6 h
after high-dose LPS injection. (E) hRETNTg− and
hRETNTg+ mice were left naive or challenged with
LPS, followed by PEC recovery and flow cytometric
analysis at 24 h after high-dose LPS. (F and G) Serum
was assayed for cytokines by Luminex. (F) Cytokines
induced 6 h after LPS treatment of hRETNTg+ and
hRETNTg− mice were plotted as a heat map.
(G) Significantly changed proinflammatory and
anti-inflammatory cytokines are represented in bar
graphs. Data are presented as mean ± SEM (n = 7–12
for survival, n = 3–5 for other parameters) and rep-
resentative of three separate experiments. ns, not
significant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001;
****P ≤ 0.0001.



























promoting anti-helminth immunity, hRetn may limit bacterial
or LPS-induced inflammatory responses. To investigate this
possibility, naive or day 14Nb-infected hRETNTg+ and hRETNTg−
mice were injected with a fatal dose of LPS and monitored for
symptoms of septic shock for 48 h. As opposed to the previous
models of endotoxic shock in which hRetn expression or treatment
occur 12 h before fatal LPS challenge, this model investigated the
effect of Nb-induced hRetn over the course of 14 d. Circulating
hRetn was modestly increased in Nb-infected mice, but signifi-
cantly increased after LPS challenge compared with naive mice,
(Fig. 3A). Although all naive hRETNTg− mice succumbed to the
fatal LPS dose, naive hRETNTg+ mice were more resistant to en-
dotoxic shock with 50% survival, suggesting homeostatic hRetn
levels are protective (Fig. 3B). Nb infection conferred par-
tial protection to hRETNTg− mice; however, this protective
effect was significantly enhanced by hRetn (100% survival of
Nb-infected hRETNTg+ mice). Cytokine quantification of the
serum from Nb-infected mice revealed equivalent levels of
LPS-induced monocyte chemoattractant protein 1 (MCP1),
IFNγ, IL-6, and IL-10 (Fig. 3C). This was in contrast to the
low- and high-dose LPS challenge, where there was signifi-
cantly reduced IFNγ and, conversely, increased IL-10. Given
Fig. 2. Therapeutic administration of hRetn during
septic shock. (A) Experimental design to test the role
of hRetn in LPS-induced sepsis. (B) Survival rate of
C57BL/6 mice treated with PBS or 500 ng/mouse
hRetn before LPS injection. (C) Rectal body temper-
ature at 6 h after LPS injection. (D) Lung vascular
permeability was measured with Evan’s blue dye at
24 h after LPS injection. (E) Serum cytokines at 6 h
after LPS injection were measured by Luminex.
(F) PECs were recovered at 24 h after LPS injection
and cells analyzed by flow cytometry. Data are pre-
sented as mean ± SEM (n = 6 for survival, n = 3–5 for
other parameters) and are representative of two
separate experiments. ns, not significant; *P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
Fig. 3. hRetn enhances helminth-mediated pro-
tection during endotoxic shock. (A) Experimental
design of hRETNTg− and hRETNTg+ mice infected
with Nb for 14 d followed by LPS challenge. Serum
hRetn was measured in naive (n) or Nb-infected mice
at −48 h (Left) or 6 h (Right) after LPS injection.
(B) Survival rate after LPS injection. (C) Serum cyto-
kines from Nb-infected and LPS-challenged hRETNTg−
and hRETNTg+ mice were evaluated by Luminex.
(D and E) PECs from Nb+LPS mice were recovered at
48 h after LPS challenge and assayed directly ex vivo.
(D) Flow cytometric analysis of PEC populations.
(E ) Representative Western blot (Left) and band
density of phosphorylated STAT3, phosphorylated
TBK1, and IκBα over endogenous β-actin was quanti-
fied for three mice per group (Right). Data are pre-
sented as mean ± SEM (n = 6–10 for survival, n= 3–4 for
other parameters) and are representative of two sep-
arate experiments. ns, not significant; *P ≤ 0.05; **P ≤
0.01; ***P ≤ 0.001.
E10402 | www.pnas.org/cgi/doi/10.1073/pnas.1716015114 Jang et al.
that mice were infected with Nb 14 d before LPS challenge, it is
possible that Nb-induced IL-10 in the hRETNTg+ mice may have
occurred earlier, or that in this chronic situation, the effect of
hRetn in reducing TNFα is more significant than its effect in
increasing IL-10.
Flow cytometric analysis of the peritoneal cavity of Nb-infected
mice revealed significantly increased neutrophils and monocytes
in the hRETNTg+ mice (Fig. 3D). These data suggest that al-
though hRetn induced by low-dose LPS and Nb infection both
protect from septic shock, the underlying immune mechanism of
protection may be different. The increased infiltration of neu-
trophils in Nb-infected hRETNTg+ mice suggests that neutrophils
are not the direct cause of hRetn-mediated protection in this
context and may not be inflammatory in helminth infection. In-
deed, previous studies have shown that Nb-induced neutrophils
exhibit significant differences in function and gene expression
compared with LPS-induced neutrophils, including a shift from
type 1 to type 2 cytokine responses (24). We next investigated
whetherNb-induced hRetn influenced pro- and anti-inflammatory
signaling after LPS injection. Peritoneal cells from Nb+LPS-
treated hRETNTg− and hRETNTg+ mice were flash frozen,
lysed, and analyzed by Western blot. We found that TLR4-
mediated anti-inflammatory signaling pathways were induced in
hRETNTg+ mice (Fig. 3E). In particular, phosphorylation of
TBK1 was increased and NF-κB inhibitor, alpha (IκBα) protein
degradation was decreased. Given that the TRIF/TBK1/IRF sig-
naling pathway mediates LPS-induced IL-10 production (25), and
IκBα inhibits NF-κB activity (26), this differential TLR4 signaling
suggests hRetn selectively induces an anti-inflammatory response.
In addition, there were elevated levels of phosphorylated STAT3,
suggesting increased IL-10 signaling (27). Together, these data
suggest Nb-induced hRetn expression protects from endotoxic
shock by promoting anti-inflammatory signaling pathways.
Human Resistin Binds to TLR4. To identify the downstream mech-
anism by which hRetn inhibits LPS-induced inflammation, we
investigated the contribution of putative hRetn receptors. There
are currently two proposed receptors for hRetn: TLR4 (19) and
cyclic adenylate associated protein 1 (CAP1) (20). Both studies
used human cell lines to demonstrate that hRetn promotes
TNFα or IL-6 production through TLR4 or CAP1. However, it is
unclear how hRetn interacts with these receptors in vivo. We
investigated RNA-seq datasets from naive or Nb-infected lungs
of hRETNTg− and hRETNTg+mice for differential expression of
Cap1 and Tlr4 (13). Although Cap1 expression was not influ-
enced by Nb infection, Tlr4 expression was significantly induced
by Nb infection (Fig. 4A). Helminth infections can introduce
endosymbiotic bacteria or create tissue injury leading to in-
creased TLR4 expression to combat potential bacterial infec-
tions (28). Furthermore, only Tlr4 expression was increased in
hRETNTg+ mice (Fig. 4A), suggesting hRetn may promote ex-
pression of its own receptor. We next used the hRetn cellular
binding assay to test whether hRetn binding was through TLR4.
Dissociated lung cells from Nb-infected Tlr4+/+ or Tlr4−/− mice
were incubated with hRetn, followed by capture with detection
antibodies to hRetn, as previously described (13). Although Tlr4+/+
monocytes (Ly6C+CD11b+) were able to bind hRetn, hRetn
binding was significantly abrogated in Tlr4−/− monocytes (Fig. 4B).
We quantified TLR4-dependent binding as percentage hRetn-
bound cells and mean fluorescence intensity in monocytes, alveo-
lar macrophages (F4/80+CD11c+), and neutrophils (Ly6G+
CD11b+) (Fig. 4 C and D). We observed TLR4-dependent binding
in monocytes and alveolar macrophages, but not neutrophils,
where hRetn binding in the absence of TLR4 was not noticeably
affected. Although TLR4 is a receptor for hRetn, there are al-
ternate hRetn receptors, which may be selectively expressed
by different cell types. Thus, neutrophils could preferentially
express an unidentified receptor for hRetn, which binds to and
modulates the proinflammatory response through an alternative
pathway. We evaluated the relative contribution of each hRetn-
bound immune cell population by measuring their frequency in
the lung (Fig. 4E). By this measurement, monocytes were the
dominant cell type that bound resistin, followed by neutrophils
and alveolar macrophages (Fig. 4F). Although the frequency of
hRetn-bound cells was relatively low (15% in monocytes and 8%
in neutrophils), this low frequency of hRetn responsive cells was
nevertheless sufficient to prevent fatal endotoxic shock. We
stained for B cells, T cells, and eosinophils; however, we did not
observe any other significant population that bound hRetn.
Given that there are no publicly available CAP1-deficient mice,
we examined direct protein–protein interaction of hRetn to
TLR4 or CAP1 as an alternative to cell binding assays. A pull-
down assay was performed using recombinant hRetn with histidine
(his)-tagged human TLR4, his-human CAP1, or his-maltose
binding protein (MBP) as a negative control (Fig. 4G). In the
pull-down elution, Western blot using anti-his antibody confirmed
that his-MBP, his-TLR4 and his-CAP1 are all pulled down by the
nickel-NTA agarose beads. In addition, when blotting the elution
fraction with anti-hRetn antibody, hRetn was only present in the
elution with his-TLR4, not his-CAP1 or his-MBP. To ensure that
this interaction was not a result of low-level LPS contamination, we
also performed this pull-down assay with mammalian cell-derived
hRetn. Similar to E. coli-derived hRetn, mammalian-derived
hRetn is only detected when pulled down with his-TLR4, not
his-CAP1 or his-MBP. Unlike the previous studies, where immu-
noprecipitation was performed with cell lysates, these data provide
direct evidence that hRetn binds to TLR4 and does not require
other proteins to form a complex. Although hRetn does not di-
rectly bind to CAP1, these data do not exclude the possibility that
hRetn might bind to CAP1 if other adaptor proteins are present.
hRetn Competes with LPS/MD2 for Binding to TLR4. Although the
X-ray crystal structure of hRetn is not available, we used the
crystal structure of mouse Retn and human TLR4 to model
hRetn binding to TLR4. This revealed that hRetn (green) and
mRetn (cyan) have the same basic structure: a trimer consisting
of a triple-helix stem (N-terminal domain) and a jelly-roll-like
head (C-terminal domain) (Fig. 5A). Next, we used the ClusPro
program to predict the interactions between hRetn and TLR4
(29). First we docked MD2, the adaptor protein that mediates
LPS binding to TLR4, and found that several possible solutions
proposed by ClusPro closely match the solved crystal structure of
the complex (30) (Fig. 5B). Subsequently, we docked the model
of hRetn into human TLR4 and found that several solutions
place the N-terminal of hRetn hexamer (blue) within the binding
pocket of TLR4 (red) for MD2 (white). In various predicted
docked models obtained with ClusPro, the junction between the
stem and head fits into the inner face of the horseshoe-like
TLR4 molecule, obstructing the binding domain for MD2 and
LPS (30). In these poses, several Retn side chains interact with
different regions of the TLR4 to make ionic interactions and
hydrogen bonds (Fig. 5C). On the basis of these structural
predictions, we hypothesized that hRetn may sterically block
LPS/MD-2 from binding to TLR4, thereby inhibiting LPS-
induced inflammation. To investigate this possibility, in vitro
competitive resistin/LPS binding assays were performed on hu-
man PBMCs. Evaluation of hRetn binding in human PBMC
revealed that CD11b+CD14+ monocytes were the dominant
population that bound hRetn, followed by SSChiCD11b+CD16+
neutrophils (Fig. 5D). We therefore assessed the potential for
hRetn to block LPS binding in monocytes. Monocytes were able
to bind LPS; however, binding was significantly abrogated if cells
were preincubated with hRetn (Fig. 5 E and F). To determine
whether hRetn inhibited downstream LPS function, we examined
human PBMCs that had been preincubated with PBS or
hRetn followed by LPS stimulation. PBMCs treated with only LPS



























generated significantly more TNFα than cells treated with hRetn+
LPS, demonstrating a functional inhibition of LPS-induced in-
flammation (Fig. 5G). These results were not an effect of endo-
toxin contamination, as the recombinant hRetn used in these
studies was derived from HEK293 cells. In addition, as LPS can
activate both TLR4 and TLR2, we used ultrapure LPS derived
from Salmonella minnesota, which only binds to and acti-
vates TLR4.
We next evaluated the accuracy of the hRetn/TLR4 modeling,
which predicted binding of the hRetn N-terminal helix to hTLR4.
To this end, we used a solid phase synthesizer to generate an
hRetn N-peptide (1–23 a.a.) and test its helical structure and
function. The N-terminal sequence of hRetn contains many amino
acids known to have a high propensity to form and stabilize alpha
helices (31). For example, the presence of an RxxE motif, which
may allow the two amino acids side chains to form an intra-
molecular salt bridge and would help stabilize the alpha helix in
both the full-length form and the synthesized peptide. Circular
dichroism analysis revealed that the synthetic agent has a signifi-
cant alpha-helical content in solution, with negative bands around
208 and 222 nm and a positive band at 190 mm (Fig. 5H). Given
the small size of the hRetn N-peptide and lack of specific anti-
bodies to the N-peptide, it was not possible to perform the
hTLR4 pulldown assay with the N-peptide. Instead, we tested the
Fig. 4. TLR4 is a receptor for hRetn. (A) Cap1 and
Tlr4 mRNA expression in naive or day 7 Nb-infected
lungs from hRETNTg− and hRETNTg+ lungs, as mea-
sured by RNA-seq. (B–D) hRetn binding of day 7 Nb-
infected Tlr4+/+ and Tlr4−/− lung cells was measured
as frequency of hRetn-bound cells and Δmean fluo-
rescence intensity. (E) Lung population frequency.
(F) Pie chart of proportion of hRetn-bound cells.
(G) Anti-His or anti-hRetn Western blot of pull-down
assay with His-tagged TLR4, His-CAP1 or His-MBP
with E.coli or 293T cell-derived hRetn. Mouse data
are presented as mean ± SEM (n = 3–4 per group),
and all data are representative of two to three sep-
arate experiments. ns, not significant; *P ≤ 0.05; **P ≤
0.01; ***P ≤ 0.001.
Fig. 5. hRetn outcompetes LPS for binding to TLR4.
(A) Prediction of the hRetn (green) structure based
on the structure of mRetn (cyan) was performed
with ClusPro web server. (B) Structural modeling of
hRetn (blue, N-terminal; green, C-terminal) and TLR4
(red) reveals that hRetn binds in the same binding
pocket of MD2 (white), the adaptor protein for LPS.
(C) Predicted molecular interactions between the
N-terminal helical trimer (cyan, red, yellow) and the
TLR4 monomer (blue). (D) Pie chart of proportion of
hRetn-bound cells in human PBMC. (E and F) LPS
binding assay in human PBMC with or without prior
incubation with hRetn (Left), followed by flow
cytometric analysis of LPS-bound CD14+CD11b+
monocytes (E) and statistical analysis (Right) (F).
(G) TNFα secretion measured in PBMC treated with
PBS or hRetn followed LPS stimulation. (H) Primary
sequence of the synthesized hRetn N-terminal pep-
tide and CD spectrum of the agent measured at
100 μM. (I) His-tagged TLR4 was incubated with
control buffer or hRetn N-terminal peptide (N-pep),
followed by incubation with 293T cell-derived Flag-
tagged hRetn, His-pulldown, and Western blot with
anti-His and anti-Flag. (J and K) LPS binding assay in
human PBMC with or without prior incubation with
hRetn or N-pep followed by flow cytometric analysis
of monocytes for LPS binding (J) and MD2/TLR4 surface expression (K). (L) TNFα secretion was measured in PBMC treated with PBS, hRetn, or N-pep, followed
by LPS stimulation. PBMC data are presented as mean ± SEM (n = 3–4 replicates), and all are representative of two to three separate experiments. *P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001.
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ability of the hRetn N-peptide to competitively inhibit subsequent
hRetn binding, using the anti-Flag antibody to detect Flag-tagged
full-length hRetn. Preincubation of hTLR4 with the hRetn N-
peptide was sufficient to abrogate binding of full-length hRetn
binding (Fig. 5I).
Last, we tested the functional ability of the hRetn N-peptide
to block LPS binding and function. We performed the bind-
ing experiments on ice to rule out the effects of LPS-induced
TLR4 endocytosis, which would have added complexity for in-
terpretation of the data. Preincubation of human PBMC with the
hRetn N-peptide or full-length hRetn inhibited LPS binding to
CD14+CD11b+ monocytes (Fig. 5J). We tested whether the
mechanism of inhibition was by preventing MD2/TLR4 complex
formation. Flow cytometric analysis of surface MD2/TLR4 revealed
that LPS treatment promotedMD2/TLR4 complex formation, but
this was abrogated by hRetn or hRetn N-peptide (Fig. 5K).
Functionally, the hRetn N-peptide was significantly more efficient
at suppressing LPS-induced TNFα than full-length hRetn (Fig.
5L). These data suggest hRetn binds TLR4 through its N-terminal
helix and effectively inhibits LPS binding and proinflammatory
function. Together, these studies support the findings from our
hRETNTg+ mouse model and validate that hRetn also inhibits
LPS responsiveness in human immune cells.
hRetn Regulates Anti-Inflammatory Signaling Pathways Through
TLR4. To investigate whether hRetn signals through TLR4, we gen-
erated hRETNTg+Tlr4−/− mice on a mRetn−/− background. Because
Tlr4−/−mice are resistant to endotoxic shock, we investigated whether
hRetn had TLR4-dependent anti-inflammatory effects under ho-
meostatic conditions. Western blot for anti-inflammatory signaling
molecules was performed on unstimulated peritoneal cells recovered
directly from hRETNTg− or hRETNTg+mice on the Tlr4+/+ or Tlr4−/−
background. Consistent with an anti-inflammatory function for
hRetn, peritoneal cells from hRETNTg+Tlr4+/+ mice had in-
creased pSTAT3 and pTBK-1 and decreased IκBα degradation
compared with hRETNTg−Tlr4+/+ mice (Fig. 6A). However, this
anti-inflammatory effect was abrogated in the absence of TLR4,
where there was no significant difference between hRETNTg+Tlr4−/−
and hRETNTg−Tlr4−/−mice. Peritoneal cells from naive mice were
also characterized by flow cytometry, which revealed modest in-
creases in monocytes and neutrophils in hRETNTg+ compared
with hRETNTg− mice on the Tlr4−/− background but no sig-
nificant differences in other cell populations, and on the Tlr4+/+
background (Fig. 6B).
To determine whether hRetn effects on TLR4 signaling were
dependent on the TBK1 and STAT3, human PBMC functional
assays with TBK1 and STAT3 pharmacologic inhibitors were
conducted. hRetn pretreatment with control DMSO significantly
reduced LPS-induced TNFα secretion and conversely increased
IL-10 expression (Fig. 6C). However, treatment with a TBK1
inhibitor before PBS or hRetn addition resulted in significantly
reduced LPS-induced TNFα and conversely increased IL-10 ex-
pression. This suggests that LPS-induced TBK1 signaling is in-
flammatory in human PBMC and is consistent with the dual
proinflammatory and anti-inflammatory functions for TBK1 de-
pendent on the context (32, 33). Given that TBK1 inhibitor treat-
ment itself caused a similar anti-inflammatory effect to hRetn, it is
difficult to definitively conclude whether hRetn functions through
TBK1. Nonetheless, hRetn’s functional effect was abrogated in the
presence of TBK1 inhibitor, suggesting that hRetn cannot further
down-regulate TNFα or up-regulate IL-10 in the absence of
TBK1 signaling. hRetn’s functional effect was also abrogated when
STAT3 signaling was inhibited. Combined, these in vivo and in vitro
data suggest that under homeostatic conditions, hRetn binds to
TLR4 and promotes STAT3 and TBK1 signaling to prevent LPS
proinflammatory effects.
Discussion
Despite major breakthroughs in the understanding of sepsis
progression, sepsis still has a high mortality rate of 30% (1). This
is the result of a lack of effective treatment options, and many
recent clinical trials have failed to reduce mortality in septic
patients (4). Thus, alternative treatments for sepsis are urgently
needed. One main pathogenic feature of sepsis is excessive in-
flammatory cytokine production, known as the systemic inflam-
matory response syndrome, which contributes to septic shock and
mortality. Here, we identify a mechanism for hRetn in protecting
against endotoxic shock by blocking LPS–TLR4 interaction and
excessive production of proinflammatory cytokines. We employ
two hRetn-expressing transgenic mouse lines, exogenous recombi-
nant hRetn treatment, and human PBMCs cultures, to show
that hRetn is critically protective against fatal LPS-induced
endotoxic shock.
Clinical studies show that patients suffering from sepsis have
elevated hRetn expression; therefore, it was initially believed
that hRetn contributes to sepsis by promoting inflammation (15).
This assumption was based on reports that LPS induces hRetn
expression, and that hRetn increases proinflammatory cytokines
production in vitro (16, 17). Our data confirm that hRetn ex-
pression is increased during septic shock. However, rather than
promoting inflammatory cytokines and LPS-induced mortality,
we propose that hRetn acts as a feedback mechanism to control
systemic inflammation by binding and inhibiting TLR4 signaling.
Although patients with more severe clinical scores for sepsis have
more circulating hRetn, our data suggest that the increased
hRetn expression may be the body’s attempt to limit the exces-
sive inflammatory immune response. Given these preclinical
sepsis data, more specific studies investigating sepsis outcome
and hRetn function are warranted to test the anti-inflammatory
and therapeutic function of hRetn in sepsis pathogenesis.
There are currently two proposed receptors for hRetn:
TLR4 and CAP1 (19, 20). Although our data show a direct in-
teraction between TLR4 and hRetn, we used hRETNTg+Tlr4−/−
mice to demonstrate that there are alternate receptors for hRetn.
Interestingly, TLR4 deficiency abrogated the anti-inflammatory
effect of hRetn in naive mice, suggesting that hRetn’s immuno-
regulatory effect is dependent on its functional interaction with
TLR4. The potential role of CAP1 in hRetn-mediated inhibition
of LPS function is unclear. Our data suggest that CAP1 is unlikely
to directly mediate protection during endotoxic shock. First, we
were unable to detect hRetn in the pull-down fraction with his-
tagged CAP1, suggesting there is no direct interaction between
hRetn and CAP1. Second, CAP1 is an intracellular receptor, with
no predicted transmembrane domain (20); thus, endocytosis of
hRetn mediated by TLR4 would be necessary for interaction with
CAP1. Previous studies have identified TLR4 as a putative re-
ceptor for hRetn; however, we prove direct hRetn-TLR4 in-
teraction that functionally affects LPS-induced signaling and
function. In addition, we provide functional evidence that hRetn
inhibits LPS binding to human immune cells and subsequent LPS
inflammatory function through a STAT3- and TBK1-dependent
mechanism. Through structural modeling and experimental stud-
ies with the N-terminal peptide of hRetn, we conclude that hRetn
interacts with the TLR4 monomer and inhibits binding of the
MD2 adaptor protein. Competitive coimmunoprecipitation and
human PBMC functional assays showed that the hRetn N-terminal is
sufficient to bind to TLR4 and inhibit LPS-induced proin-
flammatory effects. These results support the hRetn N-terminal
as the active domain of hRetn and offer the therapeutic possi-
bility of using stand-alone hRetn N-terminal helices to inhibit
LPS function.
There is 60% sequence homology between mRetn and hRetn;
however, mRetn expression is restricted to adipocytes, whereas
hRetn is predominantly expressed in myeloid cells (34). Given



























this caveat, we used transgenic hRETNTg+ mice on a mRetn−/−
background, where we validated hRetn expression by macro-
phages and monocytes (13, 16). Both C57BL/6 (mRetn+/+) mice
and mRetn−/− mice were equally susceptible to LPS-induced
mortality, suggesting that endogenous mRetn does not inhibit
LPS function. The differential expression pattern of mRetn and
hRetn, may explain this dichotomy in function, whereby mRetn
affects metabolic function and hRetn is expressed systemically
where it has an immunoregulatory function.
Although neutrophils act to limit initial bacterial or viral in-
fection, they can also contribute to sepsis through excessive pro-
duction of proinflammatory cytokines. In addition, neutrophils
contribute to organ failure and hypoperfusion through the pro-
duction of proteolytic enzymes, reactive oxygen species, and
neutrophil extracellular traps (18, 21). We observed that hRetn
inhibited neutrophil responses associated with a decrease in the
neutrophil chemoattractant GM-CSF (35), but hRetn’s effect on
neutrophils may depend on the inflammatory context. In an LPS-
alone model, hRetn reduced total neutrophil recruitment. In
contrast, hRetn increased neutrophil numbers in Nb+LPS-treated
mice, but this increased neutrophilia was associated with pro-
tection from endotoxic shock. Recent studies have shown that
helminth-induced neutrophils are significantly different from LPS-
induced neutrophils and are not proinflammatory (24); therefore,
it is likely that the hRetn-induced neutrophils in Nb-infected mice
did not contribute to LPS-induced inflammation.
hRetn binding assays of mouse and human immune cells
revealed that monocytes were the main cell-type that bound
hRetn. In addition, monocyte frequencies were increased in vivo
in hRETNTg+ mice and recombinant hRetn-treated mice. To-
gether, these data suggest that monocytes are the main down-
stream cellular target of hRetn, where hRetn acts to suppress
inflammatory pathways while promoting anti-inflammatory sig-
naling through binding TLR4. Although monocytes express
TLR4, nonimmune cells such as epithelial cells and endothelial
cells can induce TLR4 expression in inflammatory settings (36).
In addition, hRetn has been reported to act on endothelial cell
lines (37). Given that vascular dysfunction is a significant con-
tributing factor to sepsis pathogenesis, the possibility that
hRetn influences endothelial cell function warrants further
investigation. Notwithstanding this, our data strongly support an
immunoregulatory function for hRetn through direct effects
on monocytes.
Homeostatic levels of hRetn in the transgenic mice were only
50% protective against fatal endotoxic shock. Instead, low-dose
LPS treatment or Nb infection was required to boost circulating
hRetn levels for optimal protection against subsequent endotoxic
shock. It is possible that hRetn provides protection through a
similar mechanism to endotoxin tolerance, whereby hRetn stim-
ulation of TLR4 signaling causes desensitization of the LPS/
TLR signaling pathway (25, 38). TLR4 can induce two signaling
pathways: MyD88/NFκB, which is proinflammatory, and TRIF/
TBK1, which is anti-inflammatory and promotes IL-10 expression
(38). hRETNTg+ mice exhibited a TLR-4-dependent increase in
TBK-1 signaling, but a decrease in NF-κB signaling, supporting a
model in which hRetn binds to TLR4 and preferentially activates
TRIF/TBK1. Consistent with this, hRETNTg+ mice exhibited
increased IL-10 production and IL-10-associated signaling in the
endotoxic shock model. IL-10 production during sepsis is pro-
tective because it suppresses the production of TNFα and
IL-6 through activation of STAT3 signaling (39). These results
suggest that hRetn binding to TLR4 may decrease inflammation in
two ways: by inhibiting LPS binding and proinflammatory signal-
ing while increasing TBK1 activity and IL-10 production. Future
studies using STAT3- or TBK1-deficient or knockdown immune
Fig. 6. hRetn downstream signaling is TLR4-
dependent. PECs were collected from 6- to 8-wk-
old naive hRETNTg+ or hRETNTg− mice on the
Tlr4+/+ or Tlr4−/− background and analyzed directly
ex vivo. (A) Representative Western blot (Left) and
band density of phosphorylated STAT3, phosphory-
lated TBK1, and IκBα over endogenous β-actin was
quantified for three to four mice per group (Right).
(B) Flow cytometric analysis of PEC populations.
(C) The ability of hRetn to inhibit LPS-induced TNFα
and IL-10 secretion was measured in human PBMC
pretreated with control DMSO, TBK1, and STAT3
inhibitors, followed by hRetn and LPS treatment.
Percentage TNFα inhibition or IL-10 induction by
hRetn over PBS-treatment was calculated. Data are
presented as mean ± SEM (n = 3–4) and represen-
tative of two separate experiments. ns, not signifi-
cant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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cells are warranted to delineate the contribution of STAT3 or
TBK1 in the anti-inflammatory function of hRetn.
Although helminth infection is associated with an increase
in circulating LPS, there are numerous helminth-mediated
immunoregulatory mechanisms in place to reduce LPS-associated
inflammatory response. For example, helminths infections are
beneficial in sepsis by inducing IL-10 expression (6), and Fasciola
hepatica secretes fatty acid binding proteins to reduce inflammatory
responses (8). Our data suggest hookworm infection also protects
from sepsis through hRetn-dependent and hRetn-independent
mechanisms. Nb-infected hRETNTg− mice were more resistant to
LPS-induced mortality compared with naive hRETNTg− mice.
However, hRetn significantly enhanced Nb-induced protection
from endotoxic shock. These data map hRetn as a helminth-
induced regulatory pathway upstream of IL-10 expression. The
complexity of host–helminth interaction is the result of millions of
years of coevolution. For optimal outcome, the infected host must
effectively balance the immune response to limit damage caused
not only by the pathogen but also by excessive inflammation. This
balance is essential when the host is coinfected with a variety of
pathogens, such as helminths and bacteria. In this study, we show
that although hRetn exacerbates helminth burden, it protects the
host from excessive inflammation caused by endotoxic shock by
blocking interaction between LPS and TLR4. In turn, this mech-
anism is exploited by helminths to prevent their own expulsion.
Previous studies on hRetn have defined it as a detrimental
protein not only in sepsis but also in obesity, atherosclerosis, and
rheumatoid arthritis (10, 11, 34). Our study identifies a beneficial
function for hRetn, which may have evolved as a protective
mechanism against sepsis, and suggests that reexamination of the
therapeutic function of hRetn in modulating TLR4 signaling is
warranted. Because the options for treatment against sepsis are
limited, investigating the hRetn-immunoregulatory pathway or
testing hRetn N-terminal based reagents could provide a therapy
to mitigate the proinflammatory milieu found during sepsis.
Materials and Methods
Mice. Human resistin transgenic mice were generated as previously described
on a mouse Retn−/− background (16). Briefly, the human resistin gene, along
with 21,300 bp upstream and 4,248 bp downstream of the human resistin
start site, was inserted through a bacterial artificial chromosome. Genome
insertion of hRETN in the two transgenic mouse lines was determined by
Dartmouse, which sequences and analyzes thousands of SNPs throughout
the mouse genome. For the endotoxic shock model, mice were injected i.p.
with two doses of LPS (Sigma): 0.05 mg/kg LPS followed by 12 mg/kg LPS
(females) or 20 mg/kg LPS (males) 12 h later. Mice were monitored at least
twice a day and killed according to humane endpoints. For treatment with
recombinant resistin, C57BL/6 mice were injected i.p. with PBS or 0.5 μg
hRetn (Peprotech). Nb life cycle was maintained in Sprague-Dawley rats, as
previously described (13). Mice were anesthetized with isoflurane and in-
jected s.c. with 500 L3 larvae. Serum collection was by retro-orbital bleeding,
and body temperature was measured by rectal thermometer (Braintree
Scientific). All animals in the experiment were age-matched (6–8 wk old),
sex-matched, and housed in a specific pathogen-free facility.
Vascular Permeability Assay. Evan’s blue dye was used to measure vascular
permeability. Mice were anesthetized by isoflurane, and 200 μL of 0.5%
Evan’s Blue dye in PBS was injected retro-orbitally. After 10 min, mice were
killed by CO2 and perfused with 20 mL PBS. Tissue was excised, weighed, and
incubated with 500 μL N, N-dimethylformamide (Sigma) for 24 h at 55 °C.
Extracted Evan’s blue was measured at 610 nm according to a standard curve.
Binding Assay and Flow Cytometry. Single-cell suspension of lung tissue was
prepared and hRetn bindingwasmeasured as previously described (13). Briefly,
dissociated lung cells were incubated for 1 h at 4 °C with 0.5 μg recombinant
hResistin (Peprotech) or PBS, followed by 2× wash in FACS buffer, incubation
with Fc block (5 μg/mL αCD16/32 and 10 μg/mL purified rat IgG1, 5 min at
4 °C). Cells were stained with biotinylated α-hRetn (30 min at 4 °C; Peprotech)
followed by detection with BV605-conjugated streptavidin (BD) and surface
marker antibodies. The peritoneal cavity was washed and PECs recovered in
5 mL ice cold PBS. Surface marker antibodies were F4/80 (clone A3-1), SiglecF
(clone E50-2440), CD4 (clone RM4-5), Ly6C (HK1.4), CD11b (clone M1/70),
CD11c (clone N418), Ly6G (clone 1A8), MHCII (clone M5/114.15.2), CD3e
(clone 145–2C11), and CD115 (clone AFS98), purchased from Affymetrix, BD
Biosciences, or Biolegend. Cell populations were determined as follows: peri-
toneal macrophage (F4/80+CD11b+), neutrophils (Ly6G+CD11b+), eosinophils
(SiglecF+CD11c−), monocyte (Ly6C+CD11b+), alveolar macrophages (F4/80+
CD11c+). For flow cytometric analysis, all samples were run on a BD LSRII and
analyzed on FlowJo (v10).
Human PBMC. Human buffy coat was purchased from Zen-bio. Buffy coat was
overlaid on top of Histopaque-1077 and spun at 700 × g at 25 °C with no
brake, and PBMCs were recovered from the interphase. PBMCs were plated
in 96-well plates and stimulated with mammalian-derived human resistin
(1 μg/mL; LifeSpan Biosciences) or hRetn N-peptide (1 μg/mL). After 24 h,
ultrapure LPS (100 ng/mL; InvivoGen) was added and supernatants recovered
for ELISA at 24 h. Where indicated, cells were incubated for 4 h with STAT3
(5, 15-DPP, 50 μM) or TBK1 (BX-795, 1 μM) inhibitors before hRetn treatment.
For the hRetn competitive binding assay, 1 × 106 cells were incubated with
recombinant hRetn (0.5 μg), washed in PBS, and then incubated with 0.5 μg
LPS-biotin (incubations were 30 min on ice). Cells were washed in FACS
buffer, treated with Fc block, and stained with BV605-conjugated strepta-
vidin and α-human primary antibodies: CD14 (clone M5E2), CD11b (clone
M1/70), and MD2/TLR4 (clone MTS510), purchased from Affymetrix.
Cytokine Quantification. Sandwich ELISAs were performed using capture and
biotinylated antibodies for human resistin (Peprotech), IL-10, and TNFα (BD
Biosciences) according to manufacturer’s instructions. Detection was per-
formed with streptavidin-peroxidase (Jackson ImmunoResearch) and TMB
peroxidase substrate (BD Biosciences), followed by addition of 2N H2SO4.
Optical density was captured at 450 nm. Samples were compared with serial-
fold dilution of recombinant protein. For Luminex, inflammatory cytokine
kits (Affymetrix) were run according to manufacturer’s instructions and
quantified on Luminex MagPix (Luminex Corp.). For cytokine bead array,
cytokine kits from BD Bioscience were run according to manufacturer’s in-
structions on BD LSRII and analyzed using FCAP Array Software.
LAL Assay. Recombinant hResistin was tested for endotoxin contamination
using the Pierce Limulus Amebocyte Lysate assay (Thermo Scientific)
according to manufacturer’s instructions under sterile conditions.
Pull-Down Assay. First, 1 μg/mL protein His-tagged MBP, human TLR4, and hu-
man CAP1 were added to nickel-nitrilotriacetic acid-agarose beads (Invitrogen) in
binding buffer (50 mM NaH2P04, 500 mM NaCl, 10 mM Imidazole at pH 8.0) and
mixed for 1 h at 4 °C, followed by washing and 1 h incubation at 4 °C with hRetn
(E. coli-derived, Peprotech, or 293T cell-derived; LifeSpan Biosciences) in binding
buffer. Beads were washed in wash buffer (50 mM NaH2P04, 500 mM NaCl,
20 mM Imidazole at pH 8.0), and complex protein eluted with elution buffer
(50 mMNaH2P04, 500mMNaCl, 250 mM Imidazole at pH 6.0). His-MBP, His-TLR4,
and His-CAP1 were detected by anti-His antibody (Abcam), and hRetn was de-
tected by anti-hRetn antibody (donated by Mitchell Lazar) by Western Blot.
For the N-peptide binding experiment, 1 μg/mL His-tagged human TLR4 with
500 ng/mL N-peptide or 10%TFE control was added to the beads in binding
buffer and mixed for 30 min at 4 °C, followed by coimmunoprecipitation using
1 μg/mL Flag-hRetn (LifeSpan Biosciences), anti-His, or anti-Flag (Sigma).
hRetn N-Terminal Peptide Synthesis. hRetn N-terminal peptide (1–23 a.a.) was
synthesized using amicrowave- assisted solid-phase synthesizer (Liberty Blue; CEM
Corp.) and a double coupling protocol. The agent was subsequently purified by
reverse phase HPLC and characterized by high-resolution mass spectrometry and
NMR. The soluble hRetn N-peptide helical content was determined by circular
dichroism measurements in aqueous buffer containing 10% trifluoroethanol.
Signaling Western Blot. First, 1 × 106 peritoneal cells from one mouse or 3 ×
106 cell pooled from three mice per group were lysed in RIPA buffer
(150 mM sodium chloride, 1%Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 50 mM Tris·HCl, 2 mM EDTA). Proteins were boiled in loading buffer
(Bioland Scientific LLC), denatured, separated with SDS/PAGE gels, trans-
ferred to PVDF membranes (Millipore), and blocked with 5% BSA (Sigma) or
5% milk. Signaling proteins were detected with antibodies anti-pSTAT3
(Tyr705; Abcam), anti-pTBK1 (Ser172, clone D52C2), anti-IκBα, and anti-
β-actin and then incubated with anti-rabbit or mouse HRP-conjugated IgG.
All antibodies were purchased from Cell Signaling Technology. Proteins
were detected with ECL (Pierce Chemical Co.) and exposed with X-ray film
or ChemiDoc XRS+System (Bio-Rad). For quantification of protein levels,



























appropriate film exposures were scanned and the density of bands was
determined with Image J and normalized with endogenous β-actin.
Structural Predictions. The structural analysis of the TLR4–resistin interactions
was performed with the structure of human TLR4–MD2–LPS complex (PDB
code: 3FXI) and human resistin built by homology modeling. The sequence of
human resistin was downloaded from the universal protein sequence (entry
no. Q9HD89; Uniprot). Then, this sequence was used in SWISS-Model Server
for homology modeling to find a structural template. This server found mu-
rine resistin (PDB code: 1RFX) as the template with maximum sequence
identity of 57.61%. Murine resistin 3D structure was used to build the struc-
tural model for human resistin, using the server. The model of the trimer of
human resistin was used perform docking studies, with the human TLR4 using
the ClusPro web server to predict potential interactions of the resistin trimer
to the TLR4 dimer based on Van der Waal’s electrostatic interactions. As a
control, models of the complex between MD2 and TLR4 were similarly gen-
erated and compared with the experimental X-ray structure of the complex,
revealing an excellent agreement. PDBePISA server was used to confirm the
feasibility of all of the models and detailed protein–protein interactions.
Pymol software was used for all modeling manipulation.
Statistical Analysis. All statistics were generated on GraphPad Prism using,
where appropriate, log rank test, Student t test, one-way ANOVA, or two-
way ANOVA. ns, not significant (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001;
****P ≤ 0.0001).
Ethics Statement. All protocols for animal use and euthanasia were approved by
the University of California, Riverside, Institutional Animal Care and Use Com-
mittee (https://or.ucr.edu/ori/committees/iacuc.aspx; protocol A-20150028E) and
were in accordance with the National Institutes of Health Guidelines. Animal
studies are in accordance with the provisions established by the Animal Welfare
Act and the Public Health Services Policy on the Humane Care and Use of
Laboratory Animals. Human buffy coat (∼60 mL concentrated leukocytes and
erythrocytes) were collected from healthy donors with signed informed consent
by Zen-bio, Inc. Isolation of PBMC and assays were performed with the ap-
proval of the University of California, Riverside (UCR), Institutional Review
Board (HS-14–155, Exempt 4 category).
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